AZ posts solid Q1 results as Alexion merger loomsAstraZeneca’s not-for-profit coronavirus vaccine has bit into margins in Q1, although revenues were ahead of expectations as the Share XAZ posts solid Q1 results as Alexion merger loomshttps://pharmaphorum.com/news/az-posts-solid-q1-results-as-alexion-merger-looms/
Indigo Medical merges with imc groupIndigo Medical, a provider of material review, medical signatory approval services and medical communication for global pharmaceutical and Share XIndigo Medical merges with imc grouphttps://pharmaphorum.com/news/indigo-medical-merges-with-imc-group/
Microsoft puts AI at heart of digital health strategy with Nuance dealMicrosoft has made its aspirations in digital health clear with a whopping $19.7 billion deal to buy Nuance Share XMicrosoft puts AI at heart of digital health strategy with Nuance dealhttps://pharmaphorum.com/news/microsoft-puts-ai-at-heart-of-digital-health-strategy-with-nuance-deal/
Fishawack buys health economics consultancy PRMAUK comms agency Fishawack Health has acquired the health economics outcomes research (HEOR) consultancy PRMA Consulting. PRMA has Share XFishawack buys health economics consultancy PRMAhttps://pharmaphorum.com/news/fishawack-buys-health-economics-consultancy-prma/
Precision Value & Health acquires Across HealthPharma marketing specialist Precision Value & Health has acquired the specialist communications consultancy Across Health. Across Health is Share XPrecision Value & Health acquires Across Healthhttps://pharmaphorum.com/news/precision-value-health-acquires-across-health/
Amgen buys inflammatory diseases drug firm Rodeo for up to $721mAmgen has announced its second acquisition in the space of a month, snapping up Rodeo Therapeutics and its Share XAmgen buys inflammatory diseases drug firm Rodeo for up to $721mhttps://pharmaphorum.com/news/acquisitive-amgen-buys-inflammatory-diseases-drug-firm-rodeo-for-up-to-721m/
Roche expands COVID testing portfolio with $1.8bn GenMark dealRoche has said it will pay $1.8 billion for molecular testing company GenMark, boosting the Swiss company’s diagnostic Share XRoche expands COVID testing portfolio with $1.8bn GenMark dealhttps://pharmaphorum.com/news/roche-expands-covid-testing-portfolio-with-1-8bn-genmark-deal/
Takeda buys Maverick as T-Cell engager research hots upTakeda is taking its option to buy the privately held biotech Maverick Therapeutics and its T-Cell engager cancer Share XTakeda buys Maverick as T-Cell engager research hots uphttps://pharmaphorum.com/news/takeda-buys-maverick-as-t-cell-engager-research-hots-up/
Numan buys Vi Health to add digital capabilitiesNuman has added to its digital health stable with the acquisition of Sweden’s Vi Health and its suite Share XNuman buys Vi Health to add digital capabilitieshttps://pharmaphorum.com/news/numan-buys-vi-health-to-add-digital-capabilities/
